Qbiogene becomes part of MP Biomedicals

27-Sep-2004

MP Biomedicals (formerly ICN Biomedicals) is pleased to announce the acquisition of Qbiogene creating a single world-class biomedical organization with the merger of Life Science and diagnostics product offerings. With the inclusion of Qbiogene products and expertise, MP Biomedicals has expanded its industry leading portfolio of products and solutions, and will continue to provide scientists and researchers with innovative tools and superior service.

MP Biomedicals is a global corporation headquartered in Irvine, California. MP Biomedicals has operations in Northern California, New York, Ohio, Japan (Tokyo), Belgium (Brussels), Germany (Eschwege), Australia (Seven Hills), Russia (Moscow) and Singapore. Now with the addition of Qbiogene, MP Biomedicals will also have offices in France (Strasbourg), Canada (Montreal) and Carlsbad, California. For more information, visit www.mpbio.com or www.qbiogene.com.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures